Plain-English translation of NCT06507514 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new treatment approach for B-cell acute lymphoblastic leukemia (a serious blood cancer) that combines an immunotherapy drug called blinatumomab with your own stem cells. The idea is to use the medication to attack cancer cells, collect your healthy stem cells, give you a stem cell transplant, and then continue the medication afterward to help prevent the cancer from coming back.
Many patients with this type of leukemia don't have a suitable donor for a traditional stem cell transplant, or they don't want one. This trial is exploring whether using your own stem cells combined with this medication might be just as effective while avoiding the risks that come with a donor transplant.
You likely qualify if…
You likely don't qualify if…
You would receive initial chemotherapy, then two rounds of consolidation chemotherapy. Next, you'll receive the immunotherapy medication, followed by collection of your stem cells. After successful collection, you'll undergo a stem cell transplant using your own cells. Beginning three months after transplant, you'll receive four more rounds of the immunotherapy medication spaced three months apart. Throughout this process, you'll have regular clinic visits and blood work, and you'll be monitored for two years to track how well the treatment works and check for any side effects.
AI-generated summary from trial data · Jun 18, 2026 · Not medical advice
China